Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder

Qunlian Huang,1 Xiaoyan Zhong,1 Ye Yun,1 Bin Yu,2 Yilan Huang1 1Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, 2Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan Province, People’s Republic of China Object...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Huang Q, Zhong X, Yun Y, Yu B, Huang Y
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://doaj.org/article/db5d6893455c4d9fb46afab643defdfb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:db5d6893455c4d9fb46afab643defdfb
record_format dspace
spelling oai:doaj.org-article:db5d6893455c4d9fb46afab643defdfb2021-12-02T05:11:47ZEfficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder1178-2021https://doaj.org/article/db5d6893455c4d9fb46afab643defdfb2016-10-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-safety-of-multiple-doses-of-levomilnacipran-extended-rele-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Qunlian Huang,1 Xiaoyan Zhong,1 Ye Yun,1 Bin Yu,2 Yilan Huang1 1Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, 2Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan Province, People’s Republic of China Objective: The aim of this meta-analysis was to evaluate the efficacy and safety of levomilnacipran extended-release (ER) in the treatment of major depressive disorder (MDD). Methods: Randomized controlled trials were searched by electronic databases. Unpublished data were also searched by the relevant websites. Weighted mean difference (WMD) and risk ratio (RR) with 95% confidence interval (CI) were calculated and pooled using fixed-effects model or random-effects model. Results: Five randomized placebo-controlled trials including 2,637 patients were analyzed. Compared with placebo, levomilnacipran ER had a greater reduction in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score and Sheehan Disability Scale (SDS) total score (MADRS: WMD -3.49 [95% CI -4.28, -2.70; P<0.00001]; SDS: WMD -2.41 [95% CI -3.05, -1.77; P<0.00001]). Significantly more patients in levomilnacipran ER achieved MADRS response rate (RR 1.35 [95% CI 1.23, 1.47; P<0.00001]) and MADRS remission rate (RR 1.30 [95% CI 1.06, 1.59; P=0.01]). In terms of safety, more patients discontinued due to adverse events (AEs) in levomilnacipran ER compared with placebo (RR 3.15 [95% CI 2.26, 4.39; P<0.00001]), but it was generally well tolerated in each eligible trial. The most common AEs were nausea, delay in ejaculation, erectile dysfunction, tachycardia, headache and increase in heart rate. Conclusion: Levomilnacipran ER is a safe and effective short-term treatment for MDD (≤10 weeks). Long-term and head-to-head trials comparing levomilnacipran ER with other antidepressants are needed to confirm the conclusion. Keywords: levomilnacipran ER, SNRI, major depressive disorder, meta-analysisHuang QZhong XYun YYu BHuang YDove Medical PressarticleLevomilnacipran ERSNRIMajor depressive disorderMeta-analysisNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 12, Pp 2707-2714 (2016)
institution DOAJ
collection DOAJ
language EN
topic Levomilnacipran ER
SNRI
Major depressive disorder
Meta-analysis
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Levomilnacipran ER
SNRI
Major depressive disorder
Meta-analysis
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Huang Q
Zhong X
Yun Y
Yu B
Huang Y
Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
description Qunlian Huang,1 Xiaoyan Zhong,1 Ye Yun,1 Bin Yu,2 Yilan Huang1 1Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, 2Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan Province, People’s Republic of China Objective: The aim of this meta-analysis was to evaluate the efficacy and safety of levomilnacipran extended-release (ER) in the treatment of major depressive disorder (MDD). Methods: Randomized controlled trials were searched by electronic databases. Unpublished data were also searched by the relevant websites. Weighted mean difference (WMD) and risk ratio (RR) with 95% confidence interval (CI) were calculated and pooled using fixed-effects model or random-effects model. Results: Five randomized placebo-controlled trials including 2,637 patients were analyzed. Compared with placebo, levomilnacipran ER had a greater reduction in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score and Sheehan Disability Scale (SDS) total score (MADRS: WMD -3.49 [95% CI -4.28, -2.70; P<0.00001]; SDS: WMD -2.41 [95% CI -3.05, -1.77; P<0.00001]). Significantly more patients in levomilnacipran ER achieved MADRS response rate (RR 1.35 [95% CI 1.23, 1.47; P<0.00001]) and MADRS remission rate (RR 1.30 [95% CI 1.06, 1.59; P=0.01]). In terms of safety, more patients discontinued due to adverse events (AEs) in levomilnacipran ER compared with placebo (RR 3.15 [95% CI 2.26, 4.39; P<0.00001]), but it was generally well tolerated in each eligible trial. The most common AEs were nausea, delay in ejaculation, erectile dysfunction, tachycardia, headache and increase in heart rate. Conclusion: Levomilnacipran ER is a safe and effective short-term treatment for MDD (≤10 weeks). Long-term and head-to-head trials comparing levomilnacipran ER with other antidepressants are needed to confirm the conclusion. Keywords: levomilnacipran ER, SNRI, major depressive disorder, meta-analysis
format article
author Huang Q
Zhong X
Yun Y
Yu B
Huang Y
author_facet Huang Q
Zhong X
Yun Y
Yu B
Huang Y
author_sort Huang Q
title Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
title_short Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
title_full Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
title_fullStr Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
title_full_unstemmed Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
title_sort efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
publisher Dove Medical Press
publishDate 2016
url https://doaj.org/article/db5d6893455c4d9fb46afab643defdfb
work_keys_str_mv AT huangq efficacyandsafetyofmultipledosesoflevomilnacipranextendedreleaseforthetreatmentofmajordepressivedisorder
AT zhongx efficacyandsafetyofmultipledosesoflevomilnacipranextendedreleaseforthetreatmentofmajordepressivedisorder
AT yuny efficacyandsafetyofmultipledosesoflevomilnacipranextendedreleaseforthetreatmentofmajordepressivedisorder
AT yub efficacyandsafetyofmultipledosesoflevomilnacipranextendedreleaseforthetreatmentofmajordepressivedisorder
AT huangy efficacyandsafetyofmultipledosesoflevomilnacipranextendedreleaseforthetreatmentofmajordepressivedisorder
_version_ 1718400564896727040